The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.
Mohamad Adham Salkeni
No relevant relationships to disclose
Muhammad Shaalan Beg
No relevant relationships to disclose
Olugbenga Olanrele Olowokure
No relevant relationships to disclose
Hassana Fathallah
No relevant relationships to disclose
Hala Thomas
No relevant relationships to disclose
Carol A Mercer
No relevant relationships to disclose
Mahmoud Charif
No relevant relationships to disclose
Rekha T. Chaudhary
No relevant relationships to disclose
Nagla Abdel Karim
No relevant relationships to disclose
Ronald Warnick
No relevant relationships to disclose
Christopher McPherson
No relevant relationships to disclose
Ganesh Moorthy
No relevant relationships to disclose
Pankaj B Desai
No relevant relationships to disclose
Sara Kozma
Consultant or Advisory Role - Novartis
Research Funding - Novartis
George Thomas
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Olivier Rixe
Research Funding - Novartis